- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- UMEC/VI, FLUT/SAL, CAT, mMRC, Ellipta, Diskus
- Other · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 789 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- FF 400 mcg, UMEC 500 mcg, UMEC 250 mcg, VI 100 mcg
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Asthma
- Interventions
- FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI)
- Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,436 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 99
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 707 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 9
- States / cities
- Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- FF, UMEC, VI
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 14
- States / cities
- Newport Beach, California • San Diego, California • Upland, California + 11 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Placebo DISKUS, Placebo NDPI
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more